|Day Low/High||25.70 / 26.80|
|52 Wk Low/High||12.04 / 31.98|
Continued execution on multiple fronts positions the company strongly for the remainder of 2016 and beyond
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Coherus BioSciences Inc , where a total of 1,527 contracts have traded so far, representing approximately 152,700 underlying shares. That amounts to about 43.6% of CHRS's average daily trading volume over the past month of 350,515 shares.
But AbbVie still contends it should retain exclusivity on its lucrative Humira into the next decade.
The Patent Trial and Appeal Board has denied Coherus's petition to make a copy of AbbVie's Humira drug.
Management to host a call to discuss the decision
Momenta may be a good option for value-oriented investors, while Coherus may be better for those who prefer a company that is likely to gain momentum.
No Payment Due upon Return, no Obligations for Future Payments or Royalties
Year to date, shares of AbbVie are up 7%. With a gigantic patent battle looming, can the stock go higher?
Continued execution on multiple fronts positions the company strongly for the second-half of 2016 and beyond
BLA submission anticipated in the third quarter 2016
Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.
Patent Trial and Appeal Board Institutes Two Additional IPRs Against AbbVie's Patents